Z

Zentalis Pharmaceuticals
D

ZNTL

4.32000
USD
-0.12
(-2.70%)
مغلق
حجم التداول
70,279
الربح لكل سهم
-2
العائد الربحي
-
P/E
-2
حجم السوق
307,525,023
المقالات
المزيد

العنوان: Zentalis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer(Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.